The daily drug cost of Korea's novel anticancer drug 'Leclaza' is expected to be set at a level that is around ₩10,000 cheaper than ‘Tagrisso.’

Dailypharm found that the price of Yuhan Corp.’s 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Leclaza (lazertinib) was set at ₩69,000 per each 80mg tablet after drug pricing negotiations with the National Health Insurance Service (NHIS) on the 7th. If a patient takes the daily recommended dose of 240mg every day, the total cost will be around ₩207,000 per day.

The recommended daily dose of Tagrisso (osimertinib) is 80mg, and each 80mg tablet costs ₩217,782. Both prices are based